New PDUFA goal date for ezogabine in the U.S. Valeant Pharmaceuticals International (Meda's partner for ezogabine - known as retigabine outside of the U.S.) has announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for ezogabine by three months to 30 November 2010. Ezogabine is an investigational anti-epileptic drug being studied for the adjunctive treatment of adults with partial onset seizures. If questions, please contact: Anders Larnholt, Vice President Corporate Development & IR ph: +46 709-458 878
New PDUFA goal date for ezogabine in the U.S.
| Source: Meda AB